MARKET

INSM

INSM

Insmed Inc
NASDAQ
24.89
+0.12
+0.48%
Opening 09:38 05/20 EDT
OPEN
24.81
PREV CLOSE
24.77
HIGH
25.03
LOW
24.74
VOLUME
20.44K
TURNOVER
0
52 WEEK HIGH
32.00
52 WEEK LOW
18.09
MARKET CAP
3.70B
P/E (TTM)
-4.7549
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at INSM last week (0513-0517)?
Weekly Report · 9h ago
Analysts Are Bullish on Top Healthcare Stocks: Carl Zeiss Meditec (GB:0DHC), Insmed (INSM)
TipRanks · 3d ago
Insmed Is Maintained at Buy by Truist Securities
Dow Jones · 4d ago
Insmed Inc: Statement of changes in beneficial ownership of securities
Press release · 4d ago
Dell To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Wednesday
Keefe, Bruyette & Woods raised the price target for Assurant, Inc. (NYSE:AIZ) on Tuesday. Susquehanna raised Nu Holdings Ltd.’s price target from $12 to $14. Goldman Sachs boosted the price targets for Hyatt Hotels Corporation and Accenture plc.
Benzinga · 5d ago
Insmed Is Maintained at Buy by Goldman Sachs
Dow Jones · 5d ago
Insmed Price Target Raised to $49.00/Share From $40.00 by Goldman Sachs
Dow Jones · 5d ago
Goldman Sachs Maintains Buy on Insmed, Raises Price Target to $49
Benzinga · 5d ago
More
About INSM
Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).

Webull offers Insmed Inc stock information, including NASDAQ: INSM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INSM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INSM stock methods without spending real money on the virtual paper trading platform.